冠状动脉疾病；_血小板聚集抑制剂；

血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗老年ACS的研究

http://www.100md.com 《实用老年医学》 2006年第5期

冠状动脉疾病；,血小板聚集抑制剂；,老年人,1资料与方法,2结果,3讨论,参考文献

     【摘要】目的研究血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班对老年急性冠状动脉综合征(ACS)患者的有效性和安全性。方法 63例老年ACS患者随机分为替罗非班治疗组和常规治疗组，前者给予替罗非班加常规治疗，后者仅以常规药物治疗，比较2组30 d内的主要心脏不良事件(MACE)的发生率；同时观察2组患者出血的发生率以及需要输血的比例。结果 30 d内的MACE发生率替罗非班组显著低于常规治疗组(P<005)，出血、输血的比例2组无显著性差异。结论对于老年ACS患者使用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班是安全有效的，其疗效优于常规治疗。

    【主题词】冠状动脉疾病；血小板聚集抑制剂；老年人

    Study on the effects of glycoprotein Ⅱb/Ⅲa receptor inhibitors on elderly acute coronary syndrome PENG Zhisong.Jiangsu Provincial Research Institute of Geriatrics，Nanjing 210024 China； YE Fei，CHEN Shaoliang，ZHU Zhongsheng，ZHANG Junjie，LIN Song.Nanjing First Hospital，Nanjing Medical University，Nanjing 210006 China

    【Abstract】 Objective To investigate the safety and efficacy of glycoprotein Ⅱb/Ⅲa inhibitor，tirofiban，in the treatment for elderly acute coronary syndrome. Methods The present study reviewed 63 elderly ACS patients who were randomly divided into tirofiban group treated with tirofiban and conventional therapy, and conventional treatment group. The major adverse cardiac events (MACE) rates within 30 days, the incidence of bleeding and transfusion rates were analyzed and compared between two groups. Resukts MACE rates in tirofiban group were significantly higher than those in conventional group, but there were no differences in the incidence of bleeding and transfusion rates between two groups. Conckusions The results suggest that tirofiban is safe and efficacious in treating elderly ACS. ......

百拇医药网 http://www.100md.com/html/DirDu/2006/12/12/31/56/79.htm

您现在查看是摘要页，全文长 6925 字符。